Business Context and Reporting Period
Ginkgo Bioworks Holdings, Inc. filed a Form 8-K dated January 11, 2023 under Item 2.02 to announce that it issued a press release containing preliminary unaudited revenue highlights and performance updates for the year ended December 31, 2022.
Financial Metrics
- The filing indicates that preliminary revenue information was disclosed in Exhibit 99.1, but the provided filing text does not include the revenue amount or other financial metrics.
- The filing does not provide clear values for profit or loss, cash flow, margins, debt, liquidity, or cash balances.
- The results are preliminary and unaudited.
Material Changes Versus the Prior Comparable Period
The provided filing text does not describe quantitative or qualitative changes compared with the prior year or other comparable period.
Guidance, Outlook, Risks, and Unusual Items
- The filing references performance updates but does not provide clear guidance, outlook targets, management commentary, contingencies, or unusual items in the text supplied.
- Because the information is preliminary and unaudited, reported figures may differ from final results.
- The Item 2.02 information and Exhibit 99.1 are furnished rather than filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings solely through general incorporation language.
Important Facts for Investors to Verify
- Review Exhibit 99.1 for the preliminary revenue amount, performance metrics, and any management commentary.
- Verify the final audited 2022 results in the company’s subsequent Form 10-K or other reporting.
- Confirm any year-over-year comparisons, liquidity information, cash usage, debt, and updated outlook that are not included in the supplied filing text.